Gene · 90
Papers2,859
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 2,859
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Extra-neural metastases in pediatric diffuse midline gliomas, H3 K27-altered: presentation of two cases and literature review. | Front Mol Neurosci | 2023 | 37547920 | PubTator, text mining | PubMed |
| Identification and characterization of putative biomarkers and therapeutic axis in Glioblastoma multiforme microenvironment. | Front Cell Dev Biol | 2023 | 37538397 | PubTator, text mining | PubMed |
| Genetics of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Spinal Ligaments. | Curr Osteoporos Rep | 2023 | 37530996 | PubTator, text mining | PubMed |
| Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions. | Cureus | 2023 | 37521595 | PubTator, text mining | PubMed |
| Superior mesenteric artery syndrome in a patient with fibrodysplasia ossificans progressiva. | Bone Rep | 2023 | 37520933 | PubTator, text mining | PubMed |
| Polypeptide Substrate Accessibility Hypothesis: Gain-of-Function R206H Mutation Allosterically Affects Activin Receptor-like Protein Kinase Activity. | Biomolecules | 2023 | 37509165 | PubTator, text mining | PubMed |
| A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. | BMC Cancer | 2023 | 37507657 | PubTator, text mining | PubMed |
| Small Leucine-Rich Proteoglycan PODNL1 Identified as a Potential Tumor Matrix-Mediated Biomarker for Prognosis and Immunotherapy in a Pan-Cancer Setting. | Curr Issues Mol Biol | 2023 | 37504302 | PubTator, text mining | PubMed |
| Addition of heparin binding sites strongly increases the bone forming capabilities of BMP9 in vivo. | Bioact Mater | 2023 | 37502679 | PubTator, text mining | PubMed |
| Activin receptor-like kinase 3: a critical modulator of development and function of mineralized tissues. | Front Cell Dev Biol | 2023 | 37457289 | PubTator, text mining | PubMed |
| Spotlights on extracellular vesicles in hepatocellular carcinoma diagnosis and treatment: an update review. | Front Bioeng Biotechnol | 2023 | 37456728 | PubTator, text mining | PubMed |
| Interleukin-6 and pulmonary hypertension: from physiopathology to therapy. | Front Immunol | 2023 | 37449201 | PubTator, text mining | PubMed |
| Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids. | Int J Mol Sci | 2023 | 37446353 | PubTator, text mining | PubMed |
| Bone Morphogenetic Protein 13 Has Protumorigenic Effects on Hepatocellular Carcinoma Cells In Vitro. | Int J Mol Sci | 2023 | 37446238 | PubTator, text mining | PubMed |
| Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments. | Cancers (Basel) | 2023 | 37444441 | PubTator, text mining | PubMed |
| BMP4 upregulates glycogen synthesis through the SMAD/SLC2A1 (GLUT1) signaling axis in hepatocellular carcinoma (HCC) cells. | Cancer Metab | 2023 | 37443106 | PubTator, text mining | PubMed |
| PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway. | J Cell Mol Med | 2023 | 37436074 | PubTator, text mining | PubMed |
| Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. | Cancer Commun (Lond) | 2023 | 37434394 | PubTator, text mining | PubMed |
| Emerging Treatment Options for Myelofibrosis: Focus on Anemia. | Ther Clin Risk Manag | 2023 | 37404252 | PubTator, text mining | PubMed |
| Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer. | bioRxiv | 2023 | 37398244 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/90/papers?page=15